Valeant Re-Appoints Board Member
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals International Plc. has reappointed Mason Morfit to its board of directors – effective immediately. Morfit originally served on the board from 2007 to 2014 and is currently president of ValueAct Capital, a governance-orientated investment fund. He is also on the board for Microsoft Corp. and is a former director of CR Bard Inc., Immucor Inc., Advanced Medical Optics, Solexa Inc., and MSD Performance, Inc.
You may also be interested in...
Text Mining And Machine Reading: The Answer To Pharma's R&D Data Mountain?
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Adherence Issues Add Weight To Digital Trials Push
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
Appointments: Five Prime, Depomed, Gilead, Arix Bioscience and Corbus
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.